JP2004511213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004511213A5 JP2004511213A5 JP2002500948A JP2002500948A JP2004511213A5 JP 2004511213 A5 JP2004511213 A5 JP 2004511213A5 JP 2002500948 A JP2002500948 A JP 2002500948A JP 2002500948 A JP2002500948 A JP 2002500948A JP 2004511213 A5 JP2004511213 A5 JP 2004511213A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57992700A | 2000-05-26 | 2000-05-26 | |
| US21406500P | 2000-06-26 | 2000-06-26 | |
| PCT/US2001/017139 WO2001092337A2 (en) | 2000-05-26 | 2001-05-23 | Soluble ctla4 mutant molecules and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004511213A JP2004511213A (ja) | 2004-04-15 |
| JP2004511213A5 true JP2004511213A5 (enExample) | 2005-12-22 |
| JP4328525B2 JP4328525B2 (ja) | 2009-09-09 |
Family
ID=26908652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002500948A Expired - Lifetime JP4328525B2 (ja) | 2000-05-26 | 2001-05-23 | 可溶性ｃｔｌａ４突然変異体分子およびその用途 |
Country Status (41)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| HRP20030071B1 (hr) * | 2000-07-03 | 2014-01-03 | Bristol-Myers Squibb Company | Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula |
| MXPA03010568A (es) | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
| CA2482042A1 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| DE10232697A1 (de) * | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
| DE60335024D1 (de) * | 2002-12-23 | 2010-12-30 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
| JP4541157B2 (ja) * | 2002-12-23 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | タンパク質を製造するための哺乳類細胞培養法 |
| MXPA05007019A (es) | 2002-12-30 | 2005-08-18 | Amgen Inc | Terapia de combinacion con factores co-estimuladores. |
| CA2543484C (en) | 2003-10-27 | 2014-02-04 | Amgen Inc. | Modulation of immune response to an immunogen with ctla-4 and tnfbp |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| AU2006330922B2 (en) | 2005-12-20 | 2012-07-26 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
| US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
| WO2008005290A2 (en) | 2006-06-29 | 2008-01-10 | The Trustees Of Columbia University In The City Of New York | Methods for testing anti-thrombotic agents |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| KR101546441B1 (ko) | 2006-12-20 | 2015-08-24 | 엠엠알글로벌, 인코포레이티드 | 항체 및 이들의 제조 및 사용 방법 |
| CN101998965B (zh) | 2007-11-01 | 2014-03-12 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
| BRPI0920749A8 (pt) * | 2008-10-02 | 2017-12-12 | Emergent Product Dev Seattle | Proteínas de ligação de antagonista multialvo cd86 |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| US8642557B2 (en) | 2010-03-12 | 2014-02-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
| JP2014506482A (ja) | 2011-02-23 | 2014-03-17 | アムジエン・インコーポレーテツド | Ｕｖｃ露光のための細胞培養培地およびそれに関連した方法 |
| WO2013010537A1 (en) | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
| US9758566B2 (en) | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
| KR102133060B1 (ko) | 2012-05-11 | 2020-07-10 | 메디뮨 리미티드 | Ｃｔｌａ－４ 변이체 |
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| WO2014004857A1 (en) * | 2012-06-27 | 2014-01-03 | Orban Biotech Llc | Ctla4 fusion proteins for the treatment of diabetes |
| US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| AU2014376225C1 (en) | 2014-01-13 | 2025-06-05 | Amgen Inc. | Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| CN106687575B (zh) | 2014-06-04 | 2021-04-30 | 美国安进公司 | 用于收获哺乳动物细胞培养物的方法 |
| SI3227454T1 (sl) | 2014-12-01 | 2020-06-30 | Amgen Inc. | Postopek za manipuliranje ravni vsebnosti glikana glikoproteina |
| WO2016130734A1 (en) | 2015-02-11 | 2016-08-18 | Bristol-Myers Squibb Company | Use of phenolic antioxidants in cell culture for the production of proteins |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| CA2997947A1 (en) | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| JP2018536404A (ja) | 2015-11-09 | 2018-12-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法 |
| DK3515489T3 (da) | 2016-09-19 | 2026-01-26 | Oncoc4 Inc | Cd80- og cd86-bindende proteinsammensætinger og deres anvendelse |
| CN107987153A (zh) * | 2016-10-27 | 2018-05-04 | 广东香雪精准医疗技术有限公司 | 高亲和力的可溶性pd-1分子 |
| US12058986B2 (en) | 2017-04-20 | 2024-08-13 | Egenesis, Inc. | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
| CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
| EP3887394A2 (en) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| JP2022545917A (ja) | 2019-08-27 | 2022-11-01 | トニックス ファーマ リミテッド | 修飾ｔｆｆ２ポリペプチド |
| EP3931303A1 (en) | 2019-12-06 | 2022-01-05 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
| WO2021226444A2 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| BR112022024135A2 (pt) | 2020-06-18 | 2022-12-27 | Regeneron Pharma | Metodologia de peptídeo pesado para medir com precisão lisina c-terminal não processada |
| CA3189533A1 (en) | 2020-07-28 | 2022-02-03 | Seagen Inc. | Methods and systems for producing polypeptides |
| CN118647416A (zh) | 2021-12-16 | 2024-09-13 | 百时美施贵宝公司 | 用于病毒灭活的洗涤剂 |
| AU2023228815A1 (en) | 2022-03-02 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| KR100238712B1 (ko) * | 1991-06-27 | 2000-01-15 | 스티븐 비. 데이비스 | 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도 |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
| CA2346496A1 (en) * | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | Novel th2-specific molecules and uses thereof |
| HRP20030071B1 (hr) * | 2000-07-03 | 2014-01-03 | Bristol-Myers Squibb Company | Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula |
-
2001
- 2001-05-23 CN CNA2007100840790A patent/CN101255192A/zh active Pending
- 2001-05-23 TW TW097137809A patent/TWI319405B/zh not_active IP Right Cessation
- 2001-05-23 GE GE4987A patent/GEP20053658B/en unknown
- 2001-05-23 SK SK1570-2002A patent/SK288131B6/sk not_active IP Right Cessation
- 2001-05-23 AU AU6346601A patent/AU6346601A/xx active Pending
- 2001-05-23 AT AT01937764T patent/ATE271066T1/de active
- 2001-05-23 DK DK01937764T patent/DK1248802T3/da active
- 2001-05-23 EP EP04008908.8A patent/EP1536234B1/en not_active Expired - Lifetime
- 2001-05-23 HU HU0302201A patent/HU228137B1/hu active Protection Beyond IP Right Term
- 2001-05-23 UY UY26723A patent/UY26723A1/es not_active IP Right Cessation
- 2001-05-23 UA UA20021210563A patent/UA87432C2/uk unknown
- 2001-05-23 BR BR0111191-4 patent/BRPI0111191B8/pt not_active IP Right Cessation
- 2001-05-23 AU AU2001263466A patent/AU2001263466C1/en active Active
- 2001-05-23 TR TR2004/02703T patent/TR200402703T4/xx unknown
- 2001-05-23 CA CA002409748A patent/CA2409748C/en not_active Expired - Lifetime
- 2001-05-23 WO PCT/US2001/017139 patent/WO2001092337A2/en not_active Ceased
- 2001-05-23 PE PE2001000465A patent/PE20011338A1/es active IP Right Grant
- 2001-05-23 CZ CZ2002-3892A patent/CZ304451B6/cs unknown
- 2001-05-23 TW TW090112431A patent/TWI314933B/zh not_active IP Right Cessation
- 2001-05-23 MY MYPI20012427A patent/MY136113A/en unknown
- 2001-05-23 MX MXPA02011534A patent/MXPA02011534A/es active IP Right Grant
- 2001-05-23 HK HK03100239.8A patent/HK1048126B/en not_active IP Right Cessation
- 2001-05-23 CN CNB018101453A patent/CN1309735C/zh not_active Expired - Lifetime
- 2001-05-23 EE EEP200200659A patent/EE05458B1/xx active Protection Beyond IP Right Term
- 2001-05-23 EG EG20010548A patent/EG24459A/xx active
- 2001-05-23 IL IL152315A patent/IL152315A/en active Protection Beyond IP Right Term
- 2001-05-23 ES ES01937764T patent/ES2225549T3/es not_active Expired - Lifetime
- 2001-05-23 EE EEP201100050A patent/EE05557B1/xx unknown
- 2001-05-23 DE DE60104282T patent/DE60104282T2/de not_active Expired - Lifetime
- 2001-05-23 EP EP01937764A patent/EP1248802B9/en not_active Expired - Lifetime
- 2001-05-23 PT PT01937764T patent/PT1248802E/pt unknown
- 2001-05-23 AR ARP010102449A patent/AR031699A1/es active IP Right Grant
- 2001-05-23 SI SI200130186T patent/SI1248802T1/xx unknown
- 2001-05-23 PL PL366231A patent/PL206267B1/pl unknown
- 2001-05-23 EP EP15197082.9A patent/EP3029062A1/en not_active Withdrawn
- 2001-05-23 JP JP2002500948A patent/JP4328525B2/ja not_active Expired - Lifetime
- 2001-05-23 KR KR1020077017691A patent/KR100889887B1/ko not_active Expired - Lifetime
- 2001-05-23 ES ES04008908T patent/ES2571852T3/es not_active Expired - Lifetime
- 2001-05-23 KR KR1020027015946A patent/KR100895134B1/ko not_active Expired - Lifetime
- 2001-05-23 RU RU2002131588/13A patent/RU2283847C2/ru active Protection Beyond IP Right Term
-
2002
- 2002-11-04 ZA ZA200208944A patent/ZA200208944B/en unknown
- 2002-11-13 LT LT2002114A patent/LT5133B/lt not_active IP Right Cessation
- 2002-11-25 NO NO20025656A patent/NO330797B1/no not_active IP Right Cessation
- 2002-11-26 EC EC2002004365A patent/ECSP024365A/es unknown
- 2002-12-19 LV LVP-02-214A patent/LV12994B/en unknown
-
2011
- 2011-11-10 BE BE2011C041C patent/BE2011C041I2/fr unknown
- 2011-11-16 LU LU91902C patent/LU91902I2/fr unknown
- 2011-12-05 DE DE201112100063 patent/DE122011100063I1/de active Pending
- 2011-12-07 FR FR11C0053C patent/FR11C0053I2/fr active Active
- 2011-12-12 CY CY2011019C patent/CY2011019I2/el unknown
- 2011-12-15 NO NO2011027C patent/NO2011027I1/no not_active IP Right Cessation
-
2013
- 2013-04-12 HU HUS1300012C patent/HUS1300012I1/hu unknown
-
2016
- 2016-06-10 CY CY20161100511T patent/CY1117625T1/el unknown